Earnings Feed
Start Free
Home/Filings/4/0000899243-21-004962
4//SEC Filing

Flagship Ventures Fund IV General Partner LLC 4

Accession 0000899243-21-004962

CIK 0001694665other
View on SEC.govCompany Profile

Filed

Feb 3, 7:00 PM ET

Accepted

Feb 4, 5:56 PM ET

Size

31.7 KB

Accession

0000899243-21-004962

Insider Transaction Report

Form 4
Period: 2021-02-02
Evelo Biosciences, Inc.EVLO
Flagship Ventures Opportunities Fund I, L.P.
10% Owner
Transactions
  • Purchase

    Common Stock

    2021-02-02$15.00/sh+46,429$696,435→ 4,125,461 total(indirect: See Footnote)
  • Purchase

    Common Stock

    2021-02-02$15.00/sh+37,143$557,145→ 3,207,312 total(indirect: See Footnote)
  • Purchase

    Common Stock

    2021-02-02$15.00/sh+9,285$139,275→ 791,529 total(indirect: See Footnote)
  • Purchase

    Common Stock

    2021-02-02$15.00/sh+37,143$557,145→ 1,370,476 total(indirect: See Footnote)
Holdings

  • Common Stock

    (indirect: See Footnote)
    2,645,637

  • Common Stock

    (indirect: See Footnote)
    1,609,871

  • Common Stock

    (indirect: See Footnote)
    684,372

  • Common Stock

    (indirect: See Footnote)
    4,201,284

  • Common Stock

    (indirect: See Footnote)
    795,950

  • Common Stock

    (indirect: See Footnote)
    3,598,177
Nutritional Health LTP Fund General Partner LLC
10% Owner
Transactions
  • Purchase

    Common Stock

    2021-02-02$15.00/sh+37,143$557,145→ 1,370,476 total(indirect: See Footnote)
  • Purchase

    Common Stock

    2021-02-02$15.00/sh+37,143$557,145→ 3,207,312 total(indirect: See Footnote)
  • Purchase

    Common Stock

    2021-02-02$15.00/sh+46,429$696,435→ 4,125,461 total(indirect: See Footnote)
  • Purchase

    Common Stock

    2021-02-02$15.00/sh+9,285$139,275→ 791,529 total(indirect: See Footnote)
Holdings

  • Common Stock

    (indirect: See Footnote)
    684,372

  • Common Stock

    (indirect: See Footnote)
    4,201,284

  • Common Stock

    (indirect: See Footnote)
    3,598,177

  • Common Stock

    (indirect: See Footnote)
    1,609,871

  • Common Stock

    (indirect: See Footnote)
    795,950

  • Common Stock

    (indirect: See Footnote)
    2,645,637
Nutritional Health LTP Fund, L.P.
10% Owner
Transactions
  • Purchase

    Common Stock

    2021-02-02$15.00/sh+9,285$139,275→ 791,529 total(indirect: See Footnote)
  • Purchase

    Common Stock

    2021-02-02$15.00/sh+46,429$696,435→ 4,125,461 total(indirect: See Footnote)
  • Purchase

    Common Stock

    2021-02-02$15.00/sh+37,143$557,145→ 3,207,312 total(indirect: See Footnote)
  • Purchase

    Common Stock

    2021-02-02$15.00/sh+37,143$557,145→ 1,370,476 total(indirect: See Footnote)
Holdings

  • Common Stock

    (indirect: See Footnote)
    684,372

  • Common Stock

    (indirect: See Footnote)
    795,950

  • Common Stock

    (indirect: See Footnote)
    3,598,177

  • Common Stock

    (indirect: See Footnote)
    2,645,637

  • Common Stock

    (indirect: See Footnote)
    4,201,284

  • Common Stock

    (indirect: See Footnote)
    1,609,871
Flagship Ventures Fund IV General Partner LLC
10% Owner
Transactions
  • Purchase

    Common Stock

    2021-02-02$15.00/sh+46,429$696,435→ 4,125,461 total(indirect: See Footnote)
  • Purchase

    Common Stock

    2021-02-02$15.00/sh+37,143$557,145→ 1,370,476 total(indirect: See Footnote)
  • Purchase

    Common Stock

    2021-02-02$15.00/sh+37,143$557,145→ 3,207,312 total(indirect: See Footnote)
  • Purchase

    Common Stock

    2021-02-02$15.00/sh+9,285$139,275→ 791,529 total(indirect: See Footnote)
Holdings

  • Common Stock

    (indirect: See Footnote)
    2,645,637

  • Common Stock

    (indirect: See Footnote)
    1,609,871

  • Common Stock

    (indirect: See Footnote)
    684,372

  • Common Stock

    (indirect: See Footnote)
    4,201,284

  • Common Stock

    (indirect: See Footnote)
    795,950

  • Common Stock

    (indirect: See Footnote)
    3,598,177
Flagship Ventures Fund IV, L.P.
10% Owner
Transactions
  • Purchase

    Common Stock

    2021-02-02$15.00/sh+46,429$696,435→ 4,125,461 total(indirect: See Footnote)
  • Purchase

    Common Stock

    2021-02-02$15.00/sh+37,143$557,145→ 3,207,312 total(indirect: See Footnote)
  • Purchase

    Common Stock

    2021-02-02$15.00/sh+9,285$139,275→ 791,529 total(indirect: See Footnote)
  • Purchase

    Common Stock

    2021-02-02$15.00/sh+37,143$557,145→ 1,370,476 total(indirect: See Footnote)
Holdings

  • Common Stock

    (indirect: See Footnote)
    684,372

  • Common Stock

    (indirect: See Footnote)
    4,201,284

  • Common Stock

    (indirect: See Footnote)
    1,609,871

  • Common Stock

    (indirect: See Footnote)
    795,950

  • Common Stock

    (indirect: See Footnote)
    3,598,177

  • Common Stock

    (indirect: See Footnote)
    2,645,637
Flagship Ventures Fund IV-Rx, L.P.
10% Owner
Transactions
  • Purchase

    Common Stock

    2021-02-02$15.00/sh+37,143$557,145→ 3,207,312 total(indirect: See Footnote)
  • Purchase

    Common Stock

    2021-02-02$15.00/sh+9,285$139,275→ 791,529 total(indirect: See Footnote)
  • Purchase

    Common Stock

    2021-02-02$15.00/sh+37,143$557,145→ 1,370,476 total(indirect: See Footnote)
  • Purchase

    Common Stock

    2021-02-02$15.00/sh+46,429$696,435→ 4,125,461 total(indirect: See Footnote)
Holdings

  • Common Stock

    (indirect: See Footnote)
    1,609,871

  • Common Stock

    (indirect: See Footnote)
    684,372

  • Common Stock

    (indirect: See Footnote)
    2,645,637

  • Common Stock

    (indirect: See Footnote)
    4,201,284

  • Common Stock

    (indirect: See Footnote)
    795,950

  • Common Stock

    (indirect: See Footnote)
    3,598,177
Flagship Ventures Opportunities Fund I General Partner LLC
10% Owner
Transactions
  • Purchase

    Common Stock

    2021-02-02$15.00/sh+37,143$557,145→ 3,207,312 total(indirect: See Footnote)
  • Purchase

    Common Stock

    2021-02-02$15.00/sh+37,143$557,145→ 1,370,476 total(indirect: See Footnote)
  • Purchase

    Common Stock

    2021-02-02$15.00/sh+9,285$139,275→ 791,529 total(indirect: See Footnote)
  • Purchase

    Common Stock

    2021-02-02$15.00/sh+46,429$696,435→ 4,125,461 total(indirect: See Footnote)
Holdings

  • Common Stock

    (indirect: See Footnote)
    4,201,284

  • Common Stock

    (indirect: See Footnote)
    3,598,177

  • Common Stock

    (indirect: See Footnote)
    2,645,637

  • Common Stock

    (indirect: See Footnote)
    684,372

  • Common Stock

    (indirect: See Footnote)
    1,609,871

  • Common Stock

    (indirect: See Footnote)
    795,950
AFEYAN NOUBAR
Director10% Owner
Transactions
  • Purchase

    Common Stock

    2021-02-02$15.00/sh+9,285$139,275→ 791,529 total(indirect: See Footnote)
  • Purchase

    Common Stock

    2021-02-02$15.00/sh+46,429$696,435→ 4,125,461 total(indirect: See Footnote)
  • Purchase

    Common Stock

    2021-02-02$15.00/sh+37,143$557,145→ 3,207,312 total(indirect: See Footnote)
  • Purchase

    Common Stock

    2021-02-02$15.00/sh+37,143$557,145→ 1,370,476 total(indirect: See Footnote)
Holdings

  • Common Stock

    (indirect: See Footnote)
    684,372

  • Common Stock

    (indirect: See Footnote)
    795,950

  • Common Stock

    (indirect: See Footnote)
    2,645,637

  • Common Stock

    (indirect: See Footnote)
    1,609,871

  • Common Stock

    (indirect: See Footnote)
    4,201,284

  • Common Stock

    (indirect: See Footnote)
    3,598,177
Footnotes (14)
  • [F1]On February 2, 2021, Flagship Ventures Fund IV, L.P. ("Flagship Fund IV") acquired 37,143 shares pursuant to an underwritten public offering of common stock by the Issuer (the "Offering").
  • [F10]Shares held by Flagship VentureLabs V LLC ("VentureLabs V"). Flagship VentureLabs V Manager LLC ("VentureLabs V Manager") serves as manager of VentureLabs V. Flagship Pioneering is the manager of VentureLabs V Manager. Dr. Afeyan serves as sole director of Flagship Pioneering. Each of the reporting persons except for VentureLabs V disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein.
  • [F11]Shares held by Flagship Ventures Fund V, L.P. ("Flagship Fund V"). Flagship Ventures Fund V General Partner LLC ("Flagship Fund V GP") is the general partner of Flagship Fund V. Dr. Afeyan serves as sole manager of Flagship Fund V. Each of the reporting persons except for Flagship Fund V disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein.
  • [F12]Shares held by Flagship V VentureLabs Rx Fund, L.P. ("VentureLabs Rx V"). Flagship Fund V GP is the general partner of VentureLabs Rx V. Dr. Afeyan serves as sole manager of Flagship Fund V GP. Each of the reporting persons except for VentureLabs Rx V disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein.
  • [F13]Shares held by Nutritional Health Side Fund, L.P. ("Nutritional Health Side Fund"). Flagship Fund V GP is the general partner of Nutritional Health Side Fund. Dr. Afeyan serves as sole manager of Flagship Fund V GP. Each of the reporting persons except for Nutritional Health Side Fund disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein.
  • [F14]Shares held by Nutritional Health Disruptive Innovation Fund, L.P. ("Nutritional Innovation Fund"). Flagship Fund V GP is the general partner of Nutritional Innovation Fund. Dr. Afeyan serves as sole manager of Flagship Fund V GP. Each of the reporting persons except for Nutritional Innovation Fund disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein.
  • [F2]Shares held by Flagship Fund IV. Flagship Ventures Fund IV General Partner LLC ("Flagship Fund IV GP") is the general partner of Flagship Fund IV. Noubar B. Afeyan, Ph.D. ("Dr. Afeyan") is the sole manager of Flagship Fund IV GP. Each of the reporting persons except for Flagship Fund IV disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein.
  • [F3]On February 2, 2021, Flagship Ventures Fund IV-Rx, L.P. ("Flagship Fund IV-Rx") acquired 9,285 shares pursuant to the offering.
  • [F4]Shares held by Flagship Fund IV-Rx. Flagship Fund IV GP is the general partner of Flagship Fund IV-Rx. Dr. Afeyan is the sole manager of Flagship Fund IV GP. Each of the reporting persons except for Flagship Fund IV-Rx disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein.
  • [F5]On February 2, 2021, Nutritional Health LTP Fund, L.P. ("Nutritional LTP") acquired 37,143 shares pursuant to the Offering.
  • [F6]Shares held by Nutritional LTP. Nutritional Health LTP Fund General Partner LLC ("Nutritional LTP GP") is the general partner of Nutritional LTP. Dr. Afeyan is the sole member and manager of Nutritional LTP GP. Each of the reporting persons except for Nutritional LTP disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein.
  • [F7]On February 2, 2021, Flagship Ventures Opportunities Fund I, L.P. ("Flagship Opportunities I") acquired 46,429 shares pursuant to the Offering.
  • [F8]Shares held by Flagship Opportunities I. Flagship Ventures Opportunities Fund I General Partner LLC ("Flagship Opportunities GP") is the general partner of Flagship Opportunities I. Dr. Afeyan is the sole manager of Flagship Opportunities GP. Each of the reporting persons except for Flagship Opportunities I disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein.
  • [F9]Shares held by Flagship VentureLabs IV, LLC ("VentureLabs IV"). Flagship Fund IV is a member of VentureLabs IV and also serves as its manager. Flagship Fund IV GP is the general partner of Flagship Fund IV. Dr. Afeyan is the sole manager of Flagship Fund IV GP. Each of the reporting persons except for VentureLabs IV disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein.

Documents

1 file

Issuer

Evelo Biosciences, Inc.

CIK 0001694665

→
Entity typeother
IncorporatedDE

Related Parties

1
  • filerCIK 0001508051

Filing Metadata

Form type
4
Filed
Feb 3, 7:00 PM ET
Accepted
Feb 4, 5:56 PM ET
Size
31.7 KB
View on SEC.gov